CytoDyn Inc. announced that its preclinical MASH study with SMC Laboratories, Inc. has commenced, with results expected in the fall of 2024. CytoDyn believes its prior MASH study demonstrated a statistically significant benefit of leronlimab at a dosing level of 350 mg. To clarify the optimal dosing and evaluate the potential for combination therapy, SMC will be conducting a twelve-week preclinical mouse study evaluating both 350 and 700 mg dose levels, alone and in combination with Resmetirom, a drug recently approved by the FDA.

The study will evaluate leronlimab's potential role in preventing and/or reversing liver fibrosis.